Resuspend cells in assay media (Earle Salts 199X Gibco #11150, without h-EGF) containing 10 % HI-FBS and transfer 100 ul/well to assay plate (5,100 cells/well passage#2). Serial dilute human Vascular Endothelial Growth Factor (VEGF) in assay media containing 10 % HI-FBS and transfer 100ml/well to cells in assay plate. Final assay volume is 200 ml/well, containing 10 % HI-FBS, and human Vascular Endothelial Growth Factor (VEGF) as indicated 89 hours. Add 20 ml of Promega Substrate Cell Titer 96 Aqueous One Solution Reagent to each well, Incubate 37 °C and read at OD 490nm. The ED50 for the effect is typically 3.1 - 4.6 ng/ml.
Reinheit
> 95 % by SDS-PAGE.
Endotoxin-Niveau
level is less than 0.05 ng per myg (0.5 EU/myg) of human Vascular Endothelial Growth Factor (VEGF)
Vascular Endothelial Growth Factor (VEGF) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, Vascular Endothelial Growth Factor (VEGF) plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates Vascular Endothelial Growth Factor (VEGF) in the induction of tumor metastasis and intra-ocular neovascular syndromes. Vascular Endothelial Growth Factor (VEGF) signals through the three receptors, fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Synonym: VEGF 6. Formulation: Lyophilized from 25 mM HEPES and 150 mM NaCl, pH 7.0.